​

BioMarin Pharmaceutical (BMRN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BMRN Stock Forecast

BioMarin Pharmaceutical (BMRN) stock forecast, based on 38 Wall Street analysts, predicts a 12-month average price target of $104.50, with a high of $114.00 and a low of $95.00. This represents a 91.57% increase from the last price of $54.55.

$50 $63 $76 $89 $102 $115 High: $114 Avg: $104.5 Low: $95 Last Closed Price: $54.55

BMRN Stock Rating

BioMarin Pharmaceutical stock's rating consensus is Buy, based on 38 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 27 Buy (71.05%), 11 Hold (28.95%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 38 0 11 27 Strong Sell Sell Hold Buy Strong Buy

BMRN Price Target Upside V Benchmarks

TypeNameUpside
StockBioMarin Pharmaceutical91.57%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-15
Avg Price Target-$114.00$89.00
Last Closing Price$54.55$54.55$54.55
Upside/Downside-108.98%63.15%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 256165--27
Sep, 254176--27
Aug, 256166--28
Jul, 257166--29
Jun, 257166--29
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 05, 2025UBS$114.00$61.9384.08%108.98%
Jul 15, 2025Akash TewariWolfe Research$95.00$58.2363.15%74.15%
Oct 30, 2024Olivia BrayerCantor Fitzgerald$90.00$67.0034.33%64.99%
Oct 30, 2024Jack AllenRobert W. Baird$65.00$69.91-7.02%19.16%
Oct 30, 2024David LebowitzCitigroup$81.00$69.9115.86%48.49%
Oct 10, 2024Danielle BrillRaymond James$79.00$69.6013.51%44.82%
Oct 04, 2024Gena WangBarclays$86.00$69.5123.72%57.65%
Sep 18, 2024David LebowitzCitigroup$93.00$71.1430.73%70.49%
Sep 17, 2024George FarmerScotiabank$78.00$71.219.54%42.99%
Sep 17, 2024Joon LeeTruist Financial$90.00$71.2126.39%64.99%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 08, 2025H.C. WainwrightNeutralinitialise
Sep 02, 2025Raymond JamesMarket PerformOutperforminitialise
Aug 05, 2025UBSBuyBuyhold
Jul 15, 2025Wolfe ResearchOutperformOutperformhold
Nov 04, 2024WedbushNeutralOutperformupgrade
Oct 30, 2024RBC CapitalSector PerformSector Performhold
Oct 30, 2024William BlairSector PerformSector Performhold
Oct 30, 2024Cantor FitzgeraldOverweightOverweighthold
Oct 30, 2024CitigroupNeutralNeutralhold
Oct 30, 2024William BlairSector PerformMarket Performdowngrade

Financial Forecast

EPS Forecast

$-1 $0 $1 $2 $3 $4 $5 $6 $7 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.75$-0.35$0.76$0.89$2.25----
Avg Forecast$4.03$-0.35$0.69$0.98$2.26$3.22$4.07$4.97$5.99
High Forecast$4.25$-0.32$0.74$1.01$2.31$3.90$5.58$6.90$6.50
Low Forecast$3.71$-0.37$0.65$0.96$2.20$2.81$2.84$3.95$5.59
Surprise %17.87%-10.14%-9.18%-0.44%----

Revenue Forecast

$2B $2B $3B $3B $4B $5B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.86B$1.85B$2.10B$2.42B$2.85B----
Avg Forecast$1.86B$1.84B$2.10B$2.41B$2.82B$3.10B$3.40B$3.64B$3.84B
High Forecast$1.93B$1.92B$2.21B$2.50B$2.83B$3.24B$3.41B$3.65B$4.09B
Low Forecast$1.74B$1.73B$2.00B$2.39B$2.80B$2.98B$3.39B$3.63B$3.64B
Surprise %0.14%0.23%-0.06%0.27%1.24%----

Net Income Forecast

$-500M $0 $500M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$854.03M$-64.08M$141.56M$167.65M$426.86M----
Avg Forecast$1.51B$-20.04M$91.20M$167.65M$432.46M$598.00M$814.68M$974.91M$1.15B
High Forecast$1.81B$16.63M$154.19M$336.98M$442.98M$747.09M$1.07B$1.32B$1.25B
Low Forecast$1.20B$-56.71M$28.22M$-1.69M$421.94M$538.46M$543.69M$756.58M$1.07B
Surprise %-43.29%219.76%55.21%--1.30%----

BMRN Forecast FAQ

Is BioMarin Pharmaceutical stock a buy?

BioMarin Pharmaceutical stock has a consensus rating of Buy, based on 38 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 27 Buy, 11 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that BioMarin Pharmaceutical is a favorable investment for most analysts.

What is BioMarin Pharmaceutical's price target?

BioMarin Pharmaceutical's price target, set by 38 Wall Street analysts, averages $104.5 over the next 12 months. The price target range spans from $95 at the low end to $114 at the high end, suggesting a potential 91.57% change from the previous closing price of $54.55.

How does BioMarin Pharmaceutical stock forecast compare to its benchmarks?

BioMarin Pharmaceutical's stock forecast shows a 91.57% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for BioMarin Pharmaceutical over the past three months?

  • October 2025: 22.22% Strong Buy, 59.26% Buy, 18.52% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 14.81% Strong Buy, 62.96% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 21.43% Strong Buy, 57.14% Buy, 21.43% Hold, 0% Sell, 0% Strong Sell.

What is BioMarin Pharmaceutical’s EPS forecast?

BioMarin Pharmaceutical's average annual EPS forecast for its fiscal year ending in December 2025 is $3.22, marking a 43.11% increase from the reported $2.25 in 2024. Estimates for the following years are $4.07 in 2026, $4.97 in 2027, and $5.99 in 2028.

What is BioMarin Pharmaceutical’s revenue forecast?

BioMarin Pharmaceutical's average annual revenue forecast for its fiscal year ending in December 2025 is $3.1B, reflecting a 8.75% increase from the reported $2.85B in 2024. The forecast for 2026 is $3.4B, followed by $3.64B for 2027, and $3.84B for 2028.

What is BioMarin Pharmaceutical’s net income forecast?

BioMarin Pharmaceutical's net income forecast for the fiscal year ending in December 2025 stands at $598M, representing an 40.09% increase from the reported $426.86M in 2024. Projections indicate $814.68M in 2026, $974.91M in 2027, and $1.15B in 2028.